A germline HLTF mutation in familial MDS induces DNA damage accumulation through impaired PCNA polyubiquitination.


Journal

Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895

Informations de publication

Date de publication:
07 2019
Historique:
received: 09 07 2018
accepted: 27 12 2018
revised: 27 11 2018
pubmed: 31 1 2019
medline: 13 11 2019
entrez: 31 1 2019
Statut: ppublish

Résumé

Although several causal genes of familial myelodysplastic syndromes (MDS) have been identified, the genetic landscape and the molecular pathogenesis are not totally understood. To explore novel driver genes and their pathogenetic significance, we performed whole-exome sequence analysis of four individuals from a familial MDS pedigree and 10 candidate single-nucleotide variants (C9orf43, CYP7B1, EFHB, ENTPD7, FAM160B2, HELZ2, HLTF, INPP5J, ITPKB, and RYK) were identified. Knockdown screening revealed that Hltf downregulation enhanced colony-forming capacity of primary murine bone marrow (BM) stem/progenitor cells. γH2AX immunofluorescent staining assay revealed increased DNA damage in a human acute myeloid leukemia (AML) cell line ectopically expressing HLTF E259K, which was not observed in cells expressing wild-type HLTF. Silencing of HLTF in human AML cells also led to DNA damage, indicating that HLTF E259K is a loss-of-function mutation. Molecularly, we found that an E259K mutation reduced the binding capacity of HLTF with ubiquitin-conjugating enzymes, methanesulfonate sensitive 2 and ubiquitin-conjugating enzyme E2N, resulting in impaired polyubiquitination of proliferating cell nuclear antigen (PCNA) in HLTF E259K-transduced cells. In summary, our results indicate that a familial MDS-associated HLTF E259K germline mutation induces accumulation of DNA double-strand breaks, possibly through impaired PCNA polyubiquitination.

Identifiants

pubmed: 30696947
doi: 10.1038/s41375-019-0385-0
pii: 10.1038/s41375-019-0385-0
doi:

Substances chimiques

Biomarkers, Tumor 0
DNA-Binding Proteins 0
HLTF protein, human 0
PCNA protein, human 0
Proliferating Cell Nuclear Antigen 0
Transcription Factors 0
Polyubiquitin 120904-94-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1773-1782

Auteurs

Kensuke Takaoka (K)

Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.

Masahito Kawazu (M)

Department of Medical Genomics, The University of Tokyo, Tokyo, Japan.

Junji Koya (J)

Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.

Akihide Yoshimi (A)

Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.

Yosuke Masamoto (Y)

Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.

Hiroaki Maki (H)

Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.

Takashi Toya (T)

Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.

Takashi Kobayashi (T)

Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.

Yasuhito Nannya (Y)

Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.

Shunya Arai (S)

Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.

Toshihide Ueno (T)

Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Hironori Ueno (H)

Department of Hematology, Tokyo Medical Center, Tokyo, Japan.

Kenshi Suzuki (K)

Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.

Hironori Harada (H)

School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.

Atsushi Manabe (A)

Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan.

Yasuhide Hayashi (Y)

Department of Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan.

Hiroyuki Mano (H)

Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
National Cancer Center Research Institute, Tokyo, Japan.

Mineo Kurokawa (M)

Department of Hematology and Oncology, The University of Tokyo, Tokyo, Japan. kurokawa-tky@umin.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH